KOS
Chordates CSO comments on the start of the study in PM009
The first patient has now been included in Chordate Medical's open-label pilot study PM009, which aims to evaluate the effect of...
Chordate Medical trains leading neurological hospitals in the UK
On October 6-7, Chordate Medical exhibited its...
International specialist congress and upcoming milestones for Chordate Medical
Chordate Medical has once again had the opportunity to present...
Dr. Hoffmann presented Chordate Medical's results in the US
Chordate Medical's clinical study PM007 shows Kinetic Oscillation...
Otto Skolling elected to Chordate Medical's board
Recently, Otto Skolling was elected as Vice Chairman of the Board...
Chordate's treatment has an effect on allergic rhinitis
A new Italian study shows that Chordate Medicals...
Saudi market opens up to Chordate
Medical technology company Chordate Medical has recently received an order...
Trial leader on Chordate's study on chronic migraine
Chordate Medical's patient study PM007 is underway and...
Chordate presents study results to the American Headache Society
The final results from Chordate Medical's PM007 study show that KOS..
Market update Chordate Medical: “We are in a favorable position”
Chordate Medical's nerve stimulation treatment is currently being introduced at...
Chordate makes progress in Italy, China and Saudi Arabia
Chordate Medical's year-end report for 2022 does not report particularly...
Issuance takes Chordate Medical further towards exit
A strong 2022 with positive study results and several...